Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAT | P04040 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xeruborbactam SCHEMBL23655292 | 1.00 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL21012607 | 1.00 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL21012432 | 1.00 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL22854594 | 1.00 | CAT (1.00) | CAT | |
| SCHEMBL22821227 | 0.88 | CAT (0.78) | CAT | |
| SCHEMBL25739018 | 0.88 | CAT (0.78) | CAT | |
| SCHEMBL25739040 | 0.85 | CAT (0.74) | CAT | |
| SCHEMBL25739015 | 0.83 | CAT (0.71) | CAT | |
| SCHEMBL22854346 | 0.82 | CAT (0.70) | CAT | |
| SCHEMBL22854348 | 0.82 | CAT (0.70) | CAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039257-B1 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | FUJIFILM CORP (JP) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026089981-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOBACTAM AND A SOLUBILIZER | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | disclosed |
| US-12377086-B2 | Therapeutic methods, combinations and kits | Sham, Yuk Yin (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4536217-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | Fleurir Abx LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119384424-A | Novel crystal forms of boric acid compounds and preparation method thereof | 辉诺生物医药科技（杭州）有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | US | disclosed |
| CN-119301131-A | Metal beta-lactamase inhibitors | 夸祖鲁·纳塔尔大学 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024231518-A1 | COMBINATION THERAPY FOR BACTERIAL INFECTIONS COMPRISING ZINC-CHELATOR, BETA-LACTAM ANTIBIOTIC AND CYCLIC BORONATE BETA-LACTAMASE INHIBITOR | ADJUTEC PHARMA AS (NO) | 2024-11-14 | — | — | WO | disclosed |
| US-20240335453-A1 | METALLO-ß-LACTAMASE INHIBITORS | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2024-10-10 | — | — | US | disclosed |
| EP-3478693-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| WO-2020257306-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200181177-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC | 2020-06-11 | — | — | US | disclosed |
| US-20200181177-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC | 2020-06-11 | — | — | US | disclosed |
| US-10570159-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570159-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190233443-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-20190233443-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-10294249-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294249-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885 |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | PAM, ACMSD, MGAM2 | CAT 2285/4885 |
| US-20200181177-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885 |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | BTD, BLVRB, BLK | CAT 123/4885 |
| US-10570159-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885 |
| US-12590108-B2 | Boracic acid compound | ME1, GPBAR1, BCL6 | CAT 2749/4885 |
| US-12377086-B2 | Therapeutic methods, combinations and kits | MMP8, TLR7, GOT2 | CAT 122/4885 |
| US-20190233443-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885 |
| US-20240335453-A1 | METALLO-ß-LACTAMASE INHIBITORS | AOC1, CMBL, MANBA | CAT 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.